Latest news with #Ventus
Business Wire
22-05-2025
- Business
- Business Wire
Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)-- Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced the upcoming presentation of the Phase 1 safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) results of VENT-03 at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place from May 21-24 in Toronto, Canada. VENT-03 is the first oral small-molecule cyclic GMP-AMP synthase (cGAS) inhibitor to successfully complete a first-in-human Phase 1 study and was discovered using Ventus' proprietary ReSOLVE ® platform. Data from the Phase 1 study, initially announced in October 2024, showed that VENT-03 was safe and well tolerated at all tested dose levels with a favorable PK profile enabling once-daily dosing. 'We are pleased to present at LUPUS 2025 the first reported Phase 1 results for a cGAS inhibitor, demonstrating that VENT-03 has the potential to become a first- and best-in-class therapy for lupus and other autoimmune disorders,' said Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. 'Ventus is eager to unlock the potential of cGAS inhibition across multiple autoimmune diseases, with the first Phase 2 trial evaluating VENT-03 in patients with lupus to commence later this year.' The Phase 1, double-blind, placebo-controlled, first-in-human trial included 72 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The study results show that VENT-03 was safe and well tolerated up to single doses of 2000 mg once daily (QD) and multiple dosing of 900 mg QD for 10 days, which are substantially higher than our anticipated Phase 2 dose. The proportion of participants with adverse events (AEs) in the MAD cohorts was similar for VENT-03 and placebo (79% vs. 75%), and the vast majority of AEs in the study were mild and considered unrelated to the study drug. The PK profile of VENT-03 supports once-daily dosing with or without food, and the PD results demonstrate robust target engagement, supporting further clinical development. 'More than five million people worldwide are estimated to have a form of lupus. These patients can experience disease progression and severe symptoms that can affect quality of life, and currently available treatment options may not be able to adequately address these symptoms for all patients,' said Mona Kotecha, M.D., Chief Medical Officer of Ventus. 'Through targeting cGAS, VENT-03 has the potential to become a safer and more effective treatment option for patients in need, addressing key unmet needs across multiple organ systems while providing the additional benefit of once-daily oral dosing. We look forward to sharing these results and to connecting with the wider lupus community at LUPUS 2025.' Details of the poster presentation are as follows: Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers of VENT-03, a Novel cGAS Inhibitor for the Treatment of Systemic Lupus Erythematosus Authors: Xavier Valencia, Kelly Pike, Loraine Warner, Conrad Winters, Jeanne Stewart, Ramsay Beveridge, Patrick Cyr, Nadine Fradet, Amandine Chefson, Ofer Spiegelstein Abstract Number: Poster 286 Session Date: May 22 nd About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. The presence of dsDNA in the cytoplasm is often the result of cellular dysfunction, which is a hallmark of many autoimmune and inflammatory diseases. Activation of cGAS leads to cGAMP formation, activation of STING, pronounced inflammation, and tissue damage. In both patients and preclinical models of disease, the cGAS pathway has been shown to be a key driver of lupus and other inflammatory diseases, such as rheumatoid arthritis, systemic sclerosis, dermatomyositis, and Sjögren's disease. About Ventus Therapeutics Ventus Therapeutics is a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn.
National Post
29-04-2025
- Business
- National Post
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
Article content WALTHAM, Mass. & MONTREAL — Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET. Article content Article content Ventus Therapeutics is a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn. Article content Article content Article content Article content Article content Contacts Article content Article content
Business Wire
29-04-2025
- Business
- Business Wire
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)-- Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET. About Ventus Therapeutics Ventus Therapeutics is a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders. Using its proprietary drug discovery platform, ReSOLVE ®, the company has established a robust pipeline, including two wholly-owned programs. VENT-03 is a first-in-class, oral cGAS inhibitor expected to enter Phase 2 development for lupus in 2025. VENT-02 is a best-in-class, brain-penetrant, oral NLRP3 inhibitor in Phase 2 for Parkinson's disease, and is expected to enter Phase 2 development for osteoarthritis in obese patients later in 2025. In addition, Ventus has out-licensed VENT-01, a peripherally-restricted, oral NLRP3 inhibitor in Phase 1, to Novo Nordisk A/S. For more information, please visit and engage with Ventus on LinkedIn.
USA Today
26-02-2025
- Automotive
- USA Today
Fujikura releases Ventus White wood shafts
Fujikura releases Ventus White wood shafts The fourth member of the Ventus wood shaft family, Ventus White targets golfers who need help generating clubhead speed and hitting fairways. Show Caption Hide Caption TaylorMade Qi35, Qi35 LS, Qi35 Max, Qi35 Max Lite drivers TaylorMade refined the weighting and balance of the new Qi35 drivers to make it easier to gain distance with ideal spin + a better launch conditions. Fujikura's Ventus line of golf shafts uses a color system to denote launch and spin characteristics. Ventus White is the newest addition to the line, featuring the softest handle section for moderate and slower swing speeds. The new shaft incorporates VeloCore+ technology to reduce twisting and improve shot dispersion. Instead of nonsensical codes or names that don't mean anything descriptive, several shaft brands have started using color systems over the last few seasons to make it easier for consumers and fitters to understand how shafts relate to each other. For example, Fujikura offers Ventus Black for fast-swinging players who need a low-launch, low-spin driver shaft. Ventus Blue flies slightly higher and with a little more spin while Ventus Red flies higher still and has the most spin. As versions of those shafts have been released, the color coding has stayed consistent, with black being the lowest flying, then blue, and finally red, which flies the highest and spins the most. Easy. Starting today, golfers are going to see a fourth color when they go to their local pro shops and specialty stores, Ventus White. The new Ventus White, which will cost $350, has the softest handle section of any of the Ventus shafts, with a medium-stiff midsection and a firm tip. Uncut, the shaft weighs 49 grams, but cut to a traditional driver length of around 45 or 45.5 inches, it will likely drop to between 40 and 45 grams. This new lightweight offering was created for players with moderate and slower clubhead speeds who can benefit from using lighter drivers and fairway woods, and it will be offered in regular and senior-flex versions. Several driver manufacturers have begun to offer drivers specifically made for the type of player the Ventus White targets, like Callaway's Elyte Max Fast, Xxio's 13 and TaylorMade's Qi 35 Max Lite. Fujikura has also offered extremely light shafts like Air Speeder and Vista Pro in the past, but Ventus White is the first brand offering to feature VeloCore+. The addition of VeloCore+ reduces the twisting a driver shaft naturally makes on the downswing, so golfers can keep the face square more easily and tighten their dispersion patterns.
Yahoo
25-02-2025
- Automotive
- Yahoo
Fujikura releases Ventus White wood shafts
Instead of nonsensical codes or names that don't mean anything descriptive, several shaft brands have started using color systems over the last few seasons to make it easier for consumers and fitters to understand how shafts relate to each other. For example, Fujikura offers Ventus Black for fast-swinging players who need a low-launch, low-spin driver shaft. Ventus Blue flies slightly higher and with a little more spin while Ventus Red flies higher still and has the most spin. As versions of those shafts have been released, the color coding has stayed consistent, with black being the lowest flying, then blue, and finally red, which flies the highest and spins the most. Easy. Starting today, golfers are going to see a fourth color when they go to their local pro shops and specialty stores, Ventus White. The new Ventus White, which will cost $350, has the softest handle section of any of the Ventus shafts, with a medium-stiff midsection and a firm tip. Uncut, the shaft weighs 49 grams, but cut to a traditional driver length of around 45 or 45.5 inches, it will likely drop to between 40 and 45 grams. This new lightweight offering was created for players with moderate and slower clubhead speeds who can benefit from using lighter drivers and fairway woods, and it will be offered in regular and senior-flex versions. Several driver manufacturers have begun to offer drivers specifically made for the type of player the Ventus White targets, like Callaway's Elyte Max Fast, Xxio's 13 and TaylorMade's Qi 35 Max Lite. Fujikura has also offered extremely light shafts like Air Speeder and Vista Pro in the past, but Ventus White is the first brand offering to feature VeloCore+. The addition of VeloCore+ reduces the twisting a driver shaft naturally makes on the downswing, so golfers can keep the face square more easily and tighten their dispersion patterns. This article originally appeared on Golfweek: Fujikura Ventus White golf shafts arrive in stores
